<ul>
<li>CervoMed received a USPTO notice of allowance for a US patent covering neflamapimod use in “pure” dementia with Lewy bodies patients.     *      The patent targets DLB patients without substantial Alzheimer’s-like tau pathology, defined by plasma pTau levels or brain imaging.     *      Intellectual property protection is expected to run into 2042, with potential extension through patent term extension.     *      Neflamapimod has completed a Phase 2b RewinD-LB trial; Phase 3 timing depends on partnership or additional financing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606180700PRIMZONEFULLFEED9749054) on June 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</li>
</ul>

CRVO

<p>CervoMed received a USPTO notice of allowance for a patent covering neflamapimod use in pure Lewy body dementia patients, with protection extending to 2042. The patent targets DLB patients without significant Alzheimer’s-like tau pathology. Neflamapimod has completed Phase 2b trials, while Phase 3 timing depends on securing partnerships or additional financing.</p>

CervoMed wins U.S. patent allowance for neflamapimod use in pure Lewy body dementia into 2042